Rheumatology Telehealth | Telerheumatology Technology | Qventive

Rheumatology Telehealth | Telerheumatology Technology | Qventive
Qventive Healthcare

Rheumatology Telehealth Technology

Rheumatology telehealth fits specific use cases — biologics therapy follow-up between injection/infusion visits, disease activity tracking with standardized instruments, stable disease monitoring for established patients, osteoporosis medication management, and chronic rheumatologic condition follow-up. Joint exam, joint injections, infusions, and new patient evaluations require in-person. Qventive handles rheumatology telehealth with attention to appropriate fit.

Book Your Free Assessment 📞 (201) 488-2750

Understanding Rheumatology Telehealth Technology in Healthcare

The HHS OCR Breach Portal documented over 725 healthcare breaches in 2023. For practices dealing with rheumatology telehealth technology, the stakes are even higher — because downtime doesn’t just cost money, it delays patient care. That’s why Qventive approaches rheumatology telehealth technology differently than a generic IT company would.

Qventive has spent 30+ years building healthcare-exclusive IT expertise. Our Observe-Improve-Prevent methodology ensures every engagement starts with understanding your actual practice operations before recommending changes. Steve Gerbino founded this company in 1994 with a single focus: healthcare. That focus hasn’t changed.

What Makes Rheumatology IT Different

Rheumatology practices need technology partners who understand biologic medication management documentation, mips rheumatology-specific measures requirements and can configure Epic Rheumatology, NextGen for specialty-specific clinical patterns. Generic IT companies treat every practice the same — we don’t.

Three Phases to Rheumatology Telehealth Technology Excellence

Our approach to rheumatology telehealth technology follows a deliberate sequence that most IT companies skip:

Step 1: Embed with your clinical team for 3–5 days. Watch real patient encounters. Document every technology friction point — the frozen screen during check-in, the workaround your MA invented because the template doesn’t match the workflow, the report that takes 12 clicks when it should take 3.

Step 2: Design solutions based on what we observed — not on vendor demos or questionnaires. If your practice uses its EHR platform differently than the practice down the street, the configuration should reflect that.

Step 3: Implement changes in phases, monitor outcomes, and adjust. Technology that isn’t monitored drifts. We run quarterly reviews to catch issues before they become emergencies.

Why Proactive Security Matters
725+201920212023
HHS OCR Breach Portal
Rheumatology Practice — EHR Workflow Optimization
THE PROBLEM
A rheumatology practice was losing 30+ minutes per provider per day to poorly configured EHR templates. Biologic medication authorization and tracking required manual workarounds that the generic EHR setup couldn’t handle.
THE SOLUTION
Qventive’s EHR analysts redesigned specialty-specific templates, configured Epic Rheumatology integration points, and retrained clinical staff on optimized documentation workflows using our Observe-Improve-Prevent methodology.
THE RESOLUTION
Documentation time decreased by 35 minutes per provider per day within 30 days. Staff satisfaction scores improved as click-heavy workarounds were eliminated. The practice now captures quality measure data at the point of care for MIPS reporting.

Ready to Talk?

30-minute assessment. No pitch.

Book Assessment (201) 488-2750

Resources

HIPAA at HHS.gov ↗MIPS at CMS.gov ↗NIST Framework ↗
Telerheumatology Use Cases

Five operational domains.

Biologics follow-up

Between biologic injection or infusion visits, follow-up management fits telehealth. Self-administered biologics (Humira, Enbrel, Cosentyx, Taltz, Skyrizi, Rinvoq, others) — telehealth supports ongoing management well. Office-administered infusions (Remicade, Rituxan, Orencia IV, Actemra IV) require in-person for administration; follow-up between infusions fits telehealth. See our rheumatology practice management page.

Disease activity tracking

Standardized disease activity measures via telehealth — RAPID3 (patient-reported, adapts well to telehealth), CDAI (Clinical Disease Activity Index — requires joint counts but can be done with video-guided self-assessment with patient cooperation), DAS28 (requires lab values and joint counts — partial telehealth fit), BASDAI (patient-reported for AS), SLEDAI components. Treat-to-target approach with telehealth-administered measures supports ongoing management between in-person joint exams.

Stable disease monitoring

Stable RA, stable psoriatic arthritis, stable ankylosing spondylitis, stable SLE — established patients with stable disease and well-tolerated treatment fit telehealth follow-up between periodic in-person visits for joint exam and treatment adjustment assessment. Lupus with stable disease, Sjogren's follow-up, and stable inflammatory conditions.

Osteoporosis management

Osteoporosis medication management via telehealth for some medications — oral bisphosphonates (alendronate, risedronate), SERMs (raloxifene), patient-administered PTH analogs (Forteo, Tymlos). Office-administered osteoporosis medications (Prolia every 6 months, Reclast yearly, Evenity monthly) require in-person; telehealth for follow-up between injections. DEXA scan review and interpretation fits telehealth well.

What requires in-person

New patient evaluations (joint exam central to rheumatologic diagnosis), joint injections (corticosteroid or hyaluronic acid injections), infusions, musculoskeletal ultrasound, significant disease flares requiring joint exam, and any visit where joint examination would meaningfully affect treatment decisions. Joint exam cannot be adequately performed via telehealth.

Rheumatology Telehealth Technology FAQ

Yes. Biologics follow-up workflow covers treatment response tracking, adherence monitoring, adverse event documentation, and continuation decisions. Self-administered biologics (Humira, Enbrel, Cosentyx, Taltz, Skyrizi, Rinvoq, Cimzia, Simponi) fit telehealth follow-up well. Office-administered infusions (Remicade, Rituxan, Orencia IV, Actemra IV, Benlysta IV) require in-person for administration; follow-up between infusions fits telehealth. See our rheumatology practice management page.
RAPID3 (patient-reported, 3-item questionnaire) adapts particularly well to telehealth and provides useful disease activity tracking. CDAI (Clinical Disease Activity Index) requires joint counts but can be done with video-guided self-assessment in cooperative patients. DAS28 requires lab values (CRP/ESR) and joint counts — partial telehealth fit with in-person lab draws. BASDAI for ankylosing spondylitis is patient-reported and fits well. Standardized measure use supports treat-to-target approach between in-person joint exams.
Generally not recommended. Joint examination is central to rheumatologic diagnosis — synovitis detection, joint involvement patterns, joint damage assessment, and related findings require in-person examination. Initial rheumatology evaluation benefits substantially from in-person exam. Telehealth after diagnosis establishment and for stable patient management is different proposition. Some practices do initial screening via telehealth before in-person comprehensive evaluation; full telehealth-only initial evaluation not advisable.
Yes. Stable established patients with RA, PsA, AS, SLE, Sjogren's, and other chronic rheumatologic conditions fit telehealth follow-up between periodic in-person visits for joint exam. Stability indicators include stable disease activity measures, stable medication regimen with good tolerance, absence of flare symptoms, and treating physician assessment of stability. See our rheumatology practice management page.
Infusions require in-person for administration. Telehealth complements by covering pre-infusion assessment (ensuring patient is stable to proceed), follow-up between infusions (management during inter-infusion period), and decision-making about continuation, switching, or dose modification. Split workflow — in-person infusion visits + telehealth between-infusion management.
Yes for appropriate medications. Patient-administered osteoporosis medications (oral bisphosphonates, raloxifene, patient-administered PTH analogs like Forteo and Tymlos) fit telehealth follow-up. Office-administered medications (Prolia, Reclast, Evenity) require in-person administration every 6 months (Prolia), yearly (Reclast), or monthly (Evenity). Telehealth fits assessment between injections. DEXA result review and treatment planning discussion fits telehealth well.
Yes. Multi-practice rheumatology platforms (Articularis Healthcare, Bendcare, Rheumatology Associates of Long Island, and regional platforms) operate telehealth across footprints — consolidated biologics management, unified disease activity tracking, shared stable disease monitoring, and centralized infusion coordination. Our PE practice supports rheumatology platforms.
Get In Touch

Ready to Modernize Your Practice Technology?

Schedule your free practice technology assessment. Our healthcare IT specialists will review your current systems, identify gaps, and outline a roadmap built specifically for your practice.

  • 30 years of healthcare-only experience
  • EHR-certified across 7 major platforms
  • HIPAA-compliant from day one
  • No long-term contracts required
Book Your Free Assessment
Last Updated: April 2026  ·  Reviewed by: Qventive Healthcare clinical technology team

Stop refereeing IT vendors.
Start growing your practice.

Free assessment. No obligation.

Let’s Meet 📞 (201) 488-2750